ropeginterferon alfa-2b
Commercial- Indications
- Polycythemia vera
Company intelligence / Profile preview
Forus Therapeutics
Oakville, Ontario, Canadaforustherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
01
Overview
Forus Therapeutics Inc. is a Canadian biopharmaceutical company focused on advancing differentiated medicines for hematologic malignancies and other cancers. The company has an exclusive licensing agreement with PharmaEssentia to register and distribute BESREMi® (ropeginterferon alfa‑2b) for polycythemia vera in Canada, with possible expansion to other myeloproliferative neoplasm indications. It also oversees the commercialization of XPOVIO® (selinexor), a first-in-class selective inhibitor of nuclear export approved in Canada for multiple myeloma. BESREMi® has been made available via exceptional importation while Health Canada review proceeds.
- Therapeutic areas
- HematologyOncology
- Modalities
- Protein therapeutics (e.g., ropeginterferon alfa-2b)Small molecules (e.g., selinexor/XPOVIO)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
PharmaEssentia Corporation (exclusive licensing agreement for BESREMi)
Beyond the preview
Go deeper on Forus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Forus Therapeutics.